MEK activation modulates glycolysis and supports suppressive myeloid cells in TNBC
Derek A. Franklin(Vanderbilt University Medical Center), Justin M. Balko(Vanderbilt University Medical Center), Phillip T. Dean, Douglas Hinerfeld, Melinda E. Sanders(Vanderbilt University), Jenny C. Chang(Universität Hamburg), Paula I. González-Ericsson(Breast Cancer Research Foundation), Violeta Sánchez(Vanderbilt University), Michael T. Lewis(Baylor College of Medicine), Rebecca S. Cook(Vanderbilt University Medical Center), Susan R. Opalenik(Vanderbilt University), Jehovana O. Bender(Navidea Biopharmaceuticals (United States)), Stefano Cairo, Joe T. Sharick(Vanderbilt University), Christine Vaupel(Navidea Biopharmaceuticals (United States)), Melissa C. Skala(University of Wisconsin–Madison), Jennifer Bordeaux(Lineage Cell Therapeutics (United States)), Jean-Gabriel Judde(Genopole (France)), Gary Geiss(Armed Forces Institute of Pathology)
Cited by 50
Related Papers
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
|New England Journal of Medicine|2016|2.3k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k
Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming
|Nature|2017|853
Fluorescence lifetime imaging microscopy: fundamentals and advances in instrumentation, analysis, and applications
|Journal of Biomedical Optics|2020|835
Antibody validation
|BioTechniques|2010|601